The Garden State, called the “medicine chest” to the world, continues to show robust activity with life sciences firms accounting for nearly 30% of all Q2 leasing activity.
The agency’s new two-phase regulatory framework seeks to strengthen domestic supply chain and reduce foreign dependence on active pharmaceutical ingredients.
The Chinese CRDMO’s newest GMP-compliant facility in Wuxi adds seven million vials of annual capacity, expanding its bioconjugate drug product network.
